SaNOtize
An innovative biotech company, using a patented platform technology for topical delivery of NO, to treat upper respiratory and dermal infections.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $24.0m | Series B | |
| Total Funding | 000k | ||
Related Content
A pharmaceutical company that develops and commercializes nitric oxide-based therapies. Its primary technology is a Nitric Oxide Releasing Solution (NORS™) designed to treat a variety of microbial infections. The company's initial focus has been on upper respiratory infections, including COVID-19, for which it has developed a nasal spray shown to reduce viral load.
The business model revolves around the development and subsequent commercialization of its patented NORS™ technology. This includes conducting clinical trials to prove efficacy and safety, obtaining regulatory approvals in different jurisdictions, and then marketing its products to both healthcare providers and consumers. The company serves a global market, with a focus on regions where respiratory infections are prevalent. It generates revenue through the sale of its products, such as its antiviral nasal spray, and potentially through licensing its technology to other pharmaceutical companies.
Keywords: nitric oxide, antimicrobial, pharmaceutical, nasal spray, respiratory infections, antiviral, NORS, clinical trials, microbial infections, biotechnology